Etirinotecan pegol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Etirinotecan pegol
Accession Number
DB14951
Type
Small Molecule
Groups
Investigational
Description

Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).

Synonyms
Not Available
External IDs
NKTR-102
Categories
UNII
LJ16641SFT
CAS number
848779-32-8
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etirinotecan pegol.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etirinotecan pegol.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etirinotecan pegol.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Etirinotecan pegol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Nektar_Therapeutics
ATC Codes
L01XX56 — Etirinotecan pegol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced or Metastatic Solid Tumors in Patients With Hepatic Impairment1
1CompletedTreatmentCancer, Advanced / Metastatic Solid Tumors1
2Active Not RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
2CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Glioblastomas (GBM)1
2CompletedTreatmentBreast Cancer / Tumors1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentColorectal Cancers / Tumors1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Extensive-stage Small Cell Lung Cancer (SCLC) / Metastatic Breast Cancer / Non-small Cell Lung Cancer (NSCLC), Recurrent / Non-Small Cell Lung Cancer Recurrent / Recurrent Small Cell Lung Cancer (SCLC) / Refractory Small cell lung cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-small Cell Lung Cancer (NSCLC) / Tumors Metastatic to Brain1
2CompletedTreatmentMalignant Solid Tumours1
2CompletedTreatmentMetastatic Non Small Cell Lung Cancer / Recurrent Non Small Cell Lung Cancer1
2CompletedTreatmentOvarian Cancer / Tumors1
3CompletedTreatmentLocally Recurrent Breast Cancer / Metastatic Breast Cancer1
3RecruitingTreatmentBreast Cancer / Metastasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:37 / Updated on November 02, 2019 03:28